Diakonos Oncology Secures Significant Funding to Investigate DOC1021 for Refractory Melanoma Diakonos Oncology has been awarded a $7 million grant to advance research on DOC1021 in refractory melanoma, showing promise in cancer treatment.

Diakonos Oncology Secures Significant Funding to Investigate DOC1021 for Refractory Melanoma #USA #Houston #Diakonos_Oncology #DOC1021 #Refractory_Melanoma